Eli Lilly Pre-Paid Expenses 2010-2024 | LLY
Eli Lilly pre-paid expenses from 2010 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
- Eli Lilly pre-paid expenses for the quarter ending September 30, 2024 were $8.251B, a 57.22% increase year-over-year.
- Eli Lilly pre-paid expenses for 2023 were $5.541B, a 88.03% increase from 2022.
- Eli Lilly pre-paid expenses for 2022 were $2.947B, a 16.45% increase from 2021.
- Eli Lilly pre-paid expenses for 2021 were $2.531B, a 11.87% decline from 2020.
Eli Lilly Annual Pre-Paid Expenses
(Millions of US $) |
| 2023 |
$5,541 |
| 2022 |
$2,947 |
| 2021 |
$2,531 |
| 2020 |
$2,872 |
| 2019 |
$2,539 |
| 2018 |
$2,037 |
| 2017 |
$1,448 |
| 2016 |
$735 |
| 2015 |
$604 |
| 2014 |
$560 |
| 2013 |
$756 |
| 2012 |
$822 |
| 2011 |
$813 |
| 2010 |
$1,437 |
| 2009 |
$1,307 |
Eli Lilly Quarterly Pre-Paid Expenses
(Millions of US $) |
| 2024-09-30 |
$8,251 |
| 2024-06-30 |
$7,138 |
| 2024-03-31 |
$6,349 |
| 2023-12-31 |
$5,541 |
| 2023-09-30 |
$5,248 |
| 2023-06-30 |
$4,532 |
| 2023-03-31 |
$3,575 |
| 2022-12-31 |
$2,947 |
| 2022-09-30 |
$2,742 |
| 2022-06-30 |
$2,807 |
| 2022-03-31 |
$2,698 |
| 2021-12-31 |
$2,531 |
| 2021-09-30 |
$3,051 |
| 2021-06-30 |
$3,297 |
| 2021-03-31 |
$3,234 |
| 2020-12-31 |
$2,872 |
| 2020-09-30 |
$3,209 |
| 2020-06-30 |
$3,105 |
| 2020-03-31 |
$2,762 |
| 2019-12-31 |
$2,539 |
| 2019-09-30 |
$2,370 |
| 2019-06-30 |
$2,316 |
| 2019-03-31 |
$2,227 |
| 2018-12-31 |
$2,037 |
| 2018-09-30 |
$1,879 |
| 2018-06-30 |
$1,689 |
| 2018-03-31 |
$1,570 |
| 2017-12-31 |
$1,448 |
| 2017-09-30 |
$1,064 |
| 2017-06-30 |
$1,010 |
| 2017-03-31 |
$822 |
| 2016-12-31 |
$735 |
| 2016-09-30 |
$757 |
| 2016-06-30 |
$790 |
| 2016-03-31 |
$792 |
| 2015-12-31 |
$604 |
| 2015-09-30 |
$762 |
| 2015-06-30 |
$730 |
| 2015-03-31 |
$797 |
| 2014-12-31 |
$560 |
| 2014-09-30 |
$822 |
| 2014-06-30 |
$1,086 |
| 2014-03-31 |
$1,112 |
| 2013-12-31 |
$756 |
| 2013-09-30 |
$853 |
| 2013-06-30 |
$989 |
| 2013-03-31 |
$988 |
| 2012-12-31 |
$822 |
| 2012-09-30 |
$790 |
| 2012-06-30 |
$953 |
| 2012-03-31 |
$1,323 |
| 2011-12-31 |
$813 |
| 2011-09-30 |
$1,178 |
| 2011-06-30 |
$1,304 |
| 2011-03-31 |
$1,691 |
| 2010-12-31 |
$1,437 |
| 2010-09-30 |
$1,192 |
| 2010-06-30 |
$1,128 |
| 2010-03-31 |
$1,018 |
| 2009-12-31 |
$1,307 |
| 2009-09-30 |
$1,006 |
| 2009-06-30 |
$825 |
| 2009-03-31 |
$652 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$790.248B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
